ClinicalTrials.gg
CompletedNCT01920893Updated Jun 26, 2017Results posted

An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis

A Phase 2 interventional study of Placebo (for dupilumab) and Dupilumab in Nasal Polyps, sponsored by Sanofi. Completed at 14 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-06-26.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies testing dupilumab in Nasal Polyps — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Nasal Polyps.

Enrollment
7th of 16
60 · median 45
Started
2013
the only one that year
Phase 2
2 of 16
none open now
Registered
1st of 16
by date
Lead sponsor
5 of 16
Sanofi

Among the 16 studies testing dupilumab in Nasal Polyps, this one is the 7th largest by enrollment, is the only one that started in 2013, is one of 2 in phase 2, and was the 1st registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

4 of the 16 studies testing dupilumab in Nasal Polyps are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing dupilumab in Nasal Polyps, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the efficacy of dupilumab (SAR231893/REGN668) in the treatment of bilateral Nasal Polyposis (NP) by assessment of the endoscopic nasal polyp score (NPS) in comparison to placebo.

Secondary Objectives:

To evaluate effect of dupilumab with regards to:

  • symptoms of sinusitis,
  • sinus computed tomography (CT) scan,
  • NPS in the sub-group of participants with co-morbid asthma,
  • Safety and tolerability.
Read the detailed description

Screening period (4 weeks) + Randomized Treatment Period (16 weeks) + Post-Treatment Period (16 weeks) = 36 weeks.

To ensure at least 28 participants with co-morbid asthma needed for subgroup analysis, recruitment of NP participants without co-morbid asthma would stop when approximately 28 participants without asthma were randomized.

03

Conditions studied

  • Nasal Polyps

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria: participants with:

  • A minimum bilateral nasal polyp score of 5 out of a maximum score of 8 (with a unilateral score of at least 2 for each nostril) despite completion of a prior intranasal (INCS) treatment for at least 8 weeks before screening.
  • Presence of at least two of the following symptoms prior to screening: nasal blockade/obstruction/congestion or nasal discharge (anterior/posterior nasal drip); facial pain/pressure; reduction or loss of smell.

Exclusion criteria:

  • Participants \<18 or >65 years of age.
  • Sinonasal outcome test (SNOT-22) \<7.
  • Participants who had taken other drugs or prohibited therapy for this study within 2 months before screening or 5 half-lives, whichever was longer:

    • Burst of systemic corticosteroids within the 2 months before screening or were scheduled to receive systemic corticosteroids during the study period for another condition
    • INCS drops within 1 month prior to screening
    • Monoclonal antibody (mAB) and treatment
    • Anti-immunoglobulin E (IgE) therapy (omalizumab) within 130 days of Visit 1
    • Leukotriene antagonists/modifiers unless participant was on a continuous treatment for at least 30 days prior to Visit 1.
  • Participants who had undergone any nasal surgery (including polypectomy) within 6 months before screening or have had more than 5 sinonasal surgeries in the past of which maximal 2 were surgeries changing the lateral wall structure of the nose.
  • Participants with asthma having:

    • (FEV1) ≤ 60%, or .Asthma exacerbation requiring systemic (oral and/or parenteral) steroid treatment or hospitalization for >24 hours for treatment of asthma, within 3 months prior to screening or were on a dose of greater than 1000 microgram (mcg) fluticasone or an equivalent INCS.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo (for dupilumab), 2 subcutaneous injections on Day 1 as a loading dose followed by a single injection every week (QW) from Week 1 to 15 added to Mometasone furoate nasal spray (MFNS).

    Drug: Placebo (for dupilumab) · Drug: Mometasone furoate nasal spray

  • Experimental
    Dupilumab 300 mg QW

    Dupilumab, 2 Subcutaneous injections on Day 1 as a loading dose for a total of 600 mg, followed by a single 300 mg injection QW from Week 1 to 15 added to MFNS.

    Drug: Dupilumab · Drug: Mometasone furoate nasal spray

Interventions

  • DrugPlacebo (for dupilumab)

    Solution for injection; Subcutaneous injection.

  • Solution for injection; Subcutaneous injection.

    Also known as: SAR231893, REGN668

  • Nasal spray, 2 actuations in each nostril twice daily.

    Also known as: NASONEX®

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Bilateral Endoscopic Nasal Polyp Score (NPS) at Week 16

    NPS was the sum of the right and left nostril scores, as evaluated by means of nasal endoscopy. Total score ranges from 0 to 8 (scored 0 \[no polyp\] to 4 \[large polyps\] for each nostril), with a lower score indicating smaller-sized polyps.

    Time frame: Baseline, Week 16

Secondary outcomes

  1. Change From Baseline in Bilateral Endoscopic NPS at Week 16 in Participants With Asthma

    NPS was the sum of the right and left nostril scores, as evaluated by means of nasal endoscopy. Total score ranges from 0 to 8 (scored 0 \[no polyp\] to 4 \[large polyps\] for each nostril), with a lower score indicating smaller-sized polyps.

    Time frame: Baseline, Week 16

  2. Change From Baseline in Participant Reported Symptoms Scores of Sinusitis at Week 16

    Morning symptoms of sinusitis (nasal congestion/obstruction, anterior rhinorrhea \[runny nose\], posterior rhinorrhea \[post nasal drip\], and loss of sense of smell) were assessed using a 0 (no symptoms) - 3 (severe symptoms) categorical scale where higher score indicated severe symptoms.

    Time frame: Baseline, Week 16

  3. Change From Baseline in Visual Analogue Scale (VAS) for Rhinosinusitis Symptoms Severity at Week 16

    Severity of rhinosinusitis symptoms were assessed on a 0 cm (not troublesome) - 10 cm (worst thinkable troublesome) VAS where higher score indicated worst thinkable troublesome.

    Time frame: Baseline, Week 16

  4. Change From Baseline in Nasal Peak Inspiratory Flow (NPIF) at Week 16

    NPIF evaluation represents a physiologic measure of the air flow through both nasal cavities during forced inspiration and/or expiration expressed in liter per minute.

    Time frame: Baseline, Week 16

  5. Change From Baseline in Smell Test (University of Pennsylvania Smell Identification Test [UPSIT]) Scores at Week 16

    UPSIT was a 40-item test to measure the individual's ability to detect odors. Total score ranges from 0 (anosmia)-40 (normal sense of smell), lower score indicated severe smell loss.

    Time frame: Baseline, Week 16

  6. Change From Baseline in Sinus Computed Tomography (CT) Scan Assessments at Week 16: Lund-Mackay Score

    CT scan assessment included Lund-Mackay score and percent of the maxillary sinuses occupied by disease. The Lund-Mackay scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses. The total score ranges from 0 (normal) - 24 (more opacified); higher score indicated worse status.

    Time frame: Baseline, Week 16

  7. Change From Baseline in Sinus Computed Tomography (CT) Scan Assessments at Week 16: Percent Area Occupied by Disease

    CT scan assessment included Lund-Mackay score and percentage of the area of maxillary sinuses occupied by disease.

    Time frame: Baseline, Week 16

  8. Time to First Response in NPS: Kaplan-Meier Estimate at Week 16

    The time-to-first response in NPS: time from the date of randomization to the date of first NPS (defined as \>=1 point reduction from baseline score); for participants without NPS \>=1 point reduction, it was censored at the end of treatment date. The median time to first response was not estimated because the number of responses was too low in the Dupilumab arm. Therefore, alternative Kaplan-Meier statistics, the probability of response at Week 16, are presented as the descriptive measure statistics.

    Time frame: Baseline to Week 16

  9. Change From Baseline in 22-Item Sinonasal Outcome Test (SNOT-22) at Week 16

    The SNOT-22 was a validated questionnaire to assess the impact of chronic rhinosinusitis on quality of life. The total score may range from 0 (no problem)-110 (worst quality of life), higher scores represented worst quality of life; minimal clinically important change ≥ 8.90.

    Time frame: Baseline, Week 16

07

Results

Posted Jun 2, 2017
Limitations and caveats
Limitations of the trial such as small numbers of participants analysed or technical problems leading to unreliable data.

Participant flow

The study was conducted at 14 sites in 4 countries. A total of 60 participants were randomized between August 2013 and March 2014.

Participant flow — Overall Study
MilestonePlaceboDupilumab 300 mg QW
Started3030
Treated (safety population)3030
Completed2328
Not completed72
Withdrew: Adverse event52
Withdrew: Lack of efficacy20

Outcome measures

PrimaryChange From Baseline in Bilateral Endoscopic Nasal Polyp Score (NPS) at Week 16

NPS was the sum of the right and left nostril scores, as evaluated by means of nasal endoscopy. Total score ranges from 0 to 8 (scored 0 \[no polyp\] to 4 \[large polyps\] for each nostril), with a lower score indicating smaller-sized polyps.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Change From Baseline in Bilateral Endoscopic Nasal Polyp Score (NPS) at Week 16
score on a scalePlaceboDupilumab 300 mg QW
Baseline5.67 ± 0.885.87 ± 1.01
Week 165.39 ± 1.473.97 ± 1.9
Change from baseline at Week 16-0.26 ± 1.32-1.9 ± 1.76
Statistical analysis
  • Placebo vs Dupilumab 300 mg QW · Mixed Models Analysis · p = 0.0009 (Threshold for significance at 0.05 level.) · Least square (ls) mean difference: -1.55 · 95% CI -2.43 to -0.67Dupilumab 300 mg QW vs Placebo
SecondaryChange From Baseline in Bilateral Endoscopic NPS at Week 16 in Participants With Asthma

NPS was the sum of the right and left nostril scores, as evaluated by means of nasal endoscopy. Total score ranges from 0 to 8 (scored 0 \[no polyp\] to 4 \[large polyps\] for each nostril), with a lower score indicating smaller-sized polyps.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Change From Baseline in Bilateral Endoscopic NPS at Week 16 in Participants With Asthma
score on a scalePlaceboDupilumab 300 mg QW
Change From Baseline in Bilateral Endoscopic NPS at Week 16 in Participants With Asthma0.27 ± 0.88-2.4 ± 2.03
SecondaryChange From Baseline in Participant Reported Symptoms Scores of Sinusitis at Week 16

Morning symptoms of sinusitis (nasal congestion/obstruction, anterior rhinorrhea \[runny nose\], posterior rhinorrhea \[post nasal drip\], and loss of sense of smell) were assessed using a 0 (no symptoms) - 3 (severe symptoms) categorical scale where higher score indicated severe symptoms.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Change From Baseline in Participant Reported Symptoms Scores of Sinusitis at Week 16
score on a scalePlaceboDupilumab 300 mg QW
Congestion/obstruction-0.26 ± 0.7-0.95 ± 0.86
Runny nose-0.1 ± 0.58-0.62 ± 0.9
Post nasal drip-0.15 ± 0.59-0.49 ± 0.78
Loss of sense of smell-0.3 ± 0.6-1.36 ± 1.08
SecondaryChange From Baseline in Visual Analogue Scale (VAS) for Rhinosinusitis Symptoms Severity at Week 16

Severity of rhinosinusitis symptoms were assessed on a 0 cm (not troublesome) - 10 cm (worst thinkable troublesome) VAS where higher score indicated worst thinkable troublesome.

Time frame:
Baseline, Week 16
Reported as:
Mean · centimetre (cm)
Change From Baseline in Visual Analogue Scale (VAS) for Rhinosinusitis Symptoms Severity at Week 16
centimetre (cm)PlaceboDupilumab 300 mg QW
Change From Baseline in Visual Analogue Scale (VAS) for Rhinosinusitis Symptoms Severity at Week 16-1.84 ± 3.6-4.32 ± 2.75
SecondaryChange From Baseline in Nasal Peak Inspiratory Flow (NPIF) at Week 16

NPIF evaluation represents a physiologic measure of the air flow through both nasal cavities during forced inspiration and/or expiration expressed in liter per minute.

Time frame:
Baseline, Week 16
Reported as:
Mean · liter/minute
Change From Baseline in Nasal Peak Inspiratory Flow (NPIF) at Week 16
liter/minutePlaceboDupilumab 300 mg QW
NPIF-Morning28.81 ± 34.2661.91 ± 43.39
NPIF-Evening26.65 ± 34.3161.25 ± 45.91
SecondaryChange From Baseline in Smell Test (University of Pennsylvania Smell Identification Test [UPSIT]) Scores at Week 16

UPSIT was a 40-item test to measure the individual's ability to detect odors. Total score ranges from 0 (anosmia)-40 (normal sense of smell), lower score indicated severe smell loss.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on scale
Change From Baseline in Smell Test (University of Pennsylvania Smell Identification Test [UPSIT]) Scores at Week 16
score on scalePlaceboDupilumab 300 mg QW
Change From Baseline in Smell Test (University of Pennsylvania Smell Identification Test [UPSIT]) Scores at Week 16-0.17 ± 5.115.36 ± 9.61
SecondaryChange From Baseline in Sinus Computed Tomography (CT) Scan Assessments at Week 16: Lund-Mackay Score

CT scan assessment included Lund-Mackay score and percent of the maxillary sinuses occupied by disease. The Lund-Mackay scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses. The total score ranges from 0 (normal) - 24 (more opacified); higher score indicated worse status.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on scale
Change From Baseline in Sinus Computed Tomography (CT) Scan Assessments at Week 16: Lund-Mackay Score
score on scalePlaceboDupilumab 300 mg QW
Change From Baseline in Sinus Computed Tomography (CT) Scan Assessments at Week 16: Lund-Mackay Score-0.23 ± 3.74-9.24 ± 4.58
SecondaryChange From Baseline in Sinus Computed Tomography (CT) Scan Assessments at Week 16: Percent Area Occupied by Disease

CT scan assessment included Lund-Mackay score and percentage of the area of maxillary sinuses occupied by disease.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent area
Change From Baseline in Sinus Computed Tomography (CT) Scan Assessments at Week 16: Percent Area Occupied by Disease
percent areaPlaceboDupilumab 300 mg QW
Change From Baseline in Sinus Computed Tomography (CT) Scan Assessments at Week 16: Percent Area Occupied by Disease-3.92 ± 20.54-35.66 ± 24.28
SecondaryTime to First Response in NPS: Kaplan-Meier Estimate at Week 16

The time-to-first response in NPS: time from the date of randomization to the date of first NPS (defined as \>=1 point reduction from baseline score); for participants without NPS \>=1 point reduction, it was censored at the end of treatment date. The median time to first response was not estimated because the number of responses was too low in the Dupilumab arm. Therefore, alternative Kaplan-Meier statistics, the probability of response at Week 16, are presented as the descriptive measure statistics.

Time frame:
Baseline to Week 16
Reported as:
Number · Probability of response
Time to First Response in NPS: Kaplan-Meier Estimate at Week 16
Probability of responsePlaceboDupilumab 300 mg QW
Time to First Response in NPS: Kaplan-Meier Estimate at Week 160.44 (0.242 to 0.638)0.828 (0.69 to 0.965)
SecondaryChange From Baseline in 22-Item Sinonasal Outcome Test (SNOT-22) at Week 16

The SNOT-22 was a validated questionnaire to assess the impact of chronic rhinosinusitis on quality of life. The total score may range from 0 (no problem)-110 (worst quality of life), higher scores represented worst quality of life; minimal clinically important change ≥ 8.90.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Change From Baseline in 22-Item Sinonasal Outcome Test (SNOT-22) at Week 16
score on a scalePlaceboDupilumab 300 mg QW
Change From Baseline in 22-Item Sinonasal Outcome Test (SNOT-22) at Week 16-8.26 ± 17.63-29.1 ± 19.9
Post-hocChange From Baseline in Nasal Total Symptoms Score (nTSS) at Week 16

nTSS was the sum of participant-assessed nasal symptom scores for nasal congestion/obstruction, decreased/loss of sense of smell, and rhinorrhea (anterior/posterior nasal discharge), each accessed on 0-3 categorical scale. Total score ranges from 0 (no symptoms) to 9 (severe symptoms). Higher score indicated severe symptoms.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Change From Baseline in Nasal Total Symptoms Score (nTSS) at Week 16
score on a scalePlaceboDupilumab 300 mg QW
nTSS - Morning-0.68 ± 1.44-2.87 ± 2.09
nTSS - Evening-0.77 ± 1.48-2.9 ± 2.04

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 32) regardless of seriousness or relationship to investigational medicinal product (IMP).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/30 (0%)4/30 (13.3%)22/30 (73.3%)
Dupilumab 300 mg QW0/30 (0%)2/30 (6.7%)27/30 (90%)
Most frequent serious events
Most frequent serious events
EventPlaceboDupilumab 300 mg QW
Herpes zosterInfections and infestations0/301/30
Uterine cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/300/30
HypoaesthesiaNervous system disorders0/301/30
MononeuropathyNervous system disorders0/301/30
Transient ischaemic attackNervous system disorders1/300/30
ArrhythmiaCardiac disorders0/301/30
AsthmaRespiratory, thoracic and mediastinal disorders1/300/30
Nasal polypsRespiratory, thoracic and mediastinal disorders1/300/30
Pain in extremityMusculoskeletal and connective tissue disorders0/301/30
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPlaceboDupilumab 300 mg QW
NasopharyngitisInfections and infestations10/3014/30
Injection site reactionGeneral disorders2/3012/30
EpistaxisRespiratory, thoracic and mediastinal disorders2/307/30
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/307/30
HeadacheNervous system disorders5/306/30
BronchitisInfections and infestations4/301/30
Upper respiratory tract infectionInfections and infestations0/304/30
DizzinessNervous system disorders1/303/30
Upper-airway cough syndromeRespiratory, thoracic and mediastinal disorders3/300/30
Back painMusculoskeletal and connective tissue disorders0/303/30

Baseline characteristics

Baseline population included all randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboDupilumab 300 mg QWTotal
Mean49.3 ± 9.147.4 ± 9.848.4 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDupilumab 300 mg QWTotal
Female141226
Male161834
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboDupilumab 300 mg QWTotal
Hispanic or Latino022
Not Hispanic or Latino302858
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboDupilumab 300 mg QWTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White302959
More than one race000
Unknown or Not Reported000
Number of participants with asthma
Number of participants with asthma(Participants)PlaceboDupilumab 300 mg QWTotal
Yes191635
No111425
08

Study locations

14 sites
  • Investigational Site Number 840014
    Rolling Hills Estates, California 90274, United States
  • Investigational Site Number 840015
    Denver, Colorado 80230, United States
  • Investigational Site Number 840013
    Boston, Massachusetts 02114, United States
  • Investigational Site Number 840002
    Lake Oswego, Oregon 97035, United States
  • Investigational Site Number 840009
    Pittsburgh, Pennsylvania 15213, United States
  • Investigational Site Number 056001
    Gent, 9000, Belgium
  • Investigational Site Number 056002
    Leuven, 3500, Belgium
  • Investigational Site Number 724001
    Barcelona, 08036, Spain
  • Investigational Site Number 724003
    Faitanar, 46014, Spain
  • Investigational Site Number 724002
    Hospitalet De Llobregat, 08907, Spain
  • Investigational Site Number 724005
    Jerez De La Frontera, 11407, Spain
  • Investigational Site Number 724004
    Madrid, 28040, Spain
  • Investigational Site Number 752001
    Stockholm, 14186, Sweden
  • Investigational Site Number 752002
    Stockholm, 171 76, Sweden
09

References and documents

Publications

  • Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, Hellings P, Jiao L, Wang L, Evans RR, Pirozzi G, Graham NM, Swanson B, Hamilton JD, Radin A, Gandhi NA, Stahl N, Yancopoulos GD, Sutherland ER. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. JAMA. 2016 Feb 2;315(5):469-79. doi: 10.1001/jama.2015.19330. PubMed 26836729 ↗
  • Khan AH, Abbe A, Falissard B, Carita P, Bachert C, Mullol J, Reaney M, Chao J, Mannent LP, Amin N, Mahajan P, Pirozzi G, Eckert L. Data Mining of Free-Text Responses: An Innovative Approach to Analyzing Patient Perspectives on Treatment for Chronic Rhinosinusitis with Nasal Polyps in a Phase IIa Proof-of-Concept Study for Dupilumab. Patient Prefer Adherence. 2021 Nov 19;15:2577-2586. doi: 10.2147/PPA.S320242. eCollection 2021. PubMed 34848949 ↗
  • Khan AH, Reaney M, Guillemin I, Nelson L, Qin S, Kamat S, Mannent L, Amin N, Whalley D, Hopkins C. Development of Sinonasal Outcome Test (SNOT-22) Domains in Chronic Rhinosinusitis With Nasal Polyps. Laryngoscope. 2022 May;132(5):933-941. doi: 10.1002/lary.29766. Epub 2021 Aug 26. PubMed 34437720 ↗
  • Chong LY, Piromchai P, Sharp S, Snidvongs K, Webster KE, Philpott C, Hopkins C, Burton MJ. Biologics for chronic rhinosinusitis. Cochrane Database Syst Rev. 2021 Mar 12;3(3):CD013513. doi: 10.1002/14651858.CD013513.pub3. PubMed 33710614 ↗
  • Boyle JV, Lam K, Han JK. Dupilumab in the treatment of chronic rhinosinusitis with nasal polyposis. Immunotherapy. 2020 Feb;12(2):111-121. doi: 10.2217/imt-2019-0191. Epub 2020 Feb 20. PubMed 32075470 ↗
  • Bachert C, Hellings PW, Mullol J, Hamilos DL, Gevaert P, Naclerio RM, Joish VN, Chao J, Mannent LP, Amin N, Abbe A, Taniou C, Fan C, Pirozzi G, Graham NMH, Mahajan P, Staudinger H, Khan A. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy. 2020 Jan;75(1):148-157. doi: 10.1111/all.13984. Epub 2019 Oct 23. PubMed 31306495 ↗
  • Laidlaw TM, Mullol J, Fan C, Zhang D, Amin N, Khan A, Chao J, Mannent LP. Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD. J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2462-2465.e1. doi: 10.1016/j.jaip.2019.03.044. Epub 2019 Apr 4. No abstract available. PubMed 30954643 ↗
  • Jonstam K, Swanson BN, Mannent LP, Cardell LO, Tian N, Wang Y, Zhang D, Fan C, Holtappels G, Hamilton JD, Grabher A, Graham NMH, Pirozzi G, Bachert C. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis. Allergy. 2019 Apr;74(4):743-752. doi: 10.1111/all.13685. Epub 2019 Jan 21. PubMed 30488542 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2017, 2 years 7 months after primary completion. A results delay was requested in Nov 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2013
First posted
Aug 12, 2013
Start
Aug 2013
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Results delay requested
Nov 3, 2015
Results first posted
Jun 2, 2017
Last update
Jun 26, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01920893
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 12, 2013
Start date
Aug 2013
Primary completion
Nov 2014
Completion
Nov 2014
Results posted
Jun 2, 2017
Last update
Jun 26, 2017

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion